Fundz

Os Therapies

Cambridge, Maryland, United States · Biopharma, Biotechnology, Healthcare

OS Therapies is a clinical stage research company focusing on therapeutic treatments for Osteosarcoma, Breast Cancer and other solid tumors with two platform technologies: OST-HER2 to prevent metastasis and OST-tADC to debulk solid tumors.

Key facts

Headquarters
Cambridge, Maryland, United States
Employees
5
Industries
Biopharma, Biotechnology, Healthcare
Status
Public (OSTX)
Website
ostherapies.com
LinkedIn
Company page

Recent activity at Os Therapies

  • : OS Therapies Appoints Mr. Clem as Chief Commercial Officer and Mr. Knuettel as Chief Financial Officer
  • : SEC 8-K (8.01): On September 10, 2026, OS Therapies Incorporated filed a prospectus supplement with the SEC, part of its registration statement on Form S-3. This supplement pertains to the resale of up to 5,874,094 shares of common stock by the identified selling stockholders. The filing includes a legal opinion from Olshan Frome Wolosky LLP concerning the legality of the shares being offered. This event is significant as it indicates ongoing opportunities for shareholders to divest holdings, which could impact market liquidity and shareholder dynamics. The effective registration statement was previously filed on August 8, 2025, and declared effective on August 25, 2025.
  • : SEC 8-K (5.02): On September 9, 2026, stockholders of OS Therapies Incorporated approved an amendment and restatement of the company’s 2023 Incentive Compensation Plan during the Annual Meeting. This Amended and Restated Plan introduces significant updates aimed at optimizing the company's incentive structure for its executives and directors. The details of these amendments are thoroughly discussed in the Proxy Statement filed with the SEC on July 24, 2026. The approval reflects the company's commitment to enhancing its governance and compensatory practices to align with shareholder interests.
  • : OS THERAPIES
  • : SEC 8-K (1.01): On August 21, 2026, OS Therapies Incorporated entered into a Material Definitive Agreement with Jefferies LLC, termed the Open Market Sale Agreement. This agreement allows the Company to offer and sell shares of its common stock through Jefferies in connection with the Company's at-the-market offering program. A prospectus supplement for this ATM Offering was also filed with the SEC on August 21, 2026, under the Company's shelf registration statement effective from August 25, 2025. This strategic move is aimed at raising capital and enhancing liquidity for OS Therapies, indicating positive growth prospects and investor engagement following the ongoing market conditions.
  • : OS THERAPIES
  • : OS THERAPIES
  • : OS THERAPIES
  • : SEC 8-K (5.02): On October 21, 2025, the stockholders of OS Therapies Incorporated approved an amendment to the Company’s 2023 Incentive Compensation Plan during its annual meeting. This Plan Amendment alters key aspects of the existing compensation structure, impacting potential compensatory arrangements for certain officers. The amendments highlight strategic shifts in executive compensation, which may aim to align management incentives with company performance. The significant changes were outlined in the definitive proxy statement filed with the SEC on August 25, 2025, thereby ensuring transparency in the modifications.
  • : OS THERAPIES

Os Therapies funding history

DateRoundAmount
Aug 2026Venture$5.0M
Jul 2026Venture$1.6M
Mar 2026Venture$2.0M
Jan 2026Venture$3.5M
Sep 2025Venture$3.8M

Leadership

  • Theodore Search, Director
  • John Ciccio, Director
  • Joacim Borg, Director
  • Colin Goddard, Director
  • Paul Romness, Executive Officer, Director
  • Paul Romness, Executive Officer, Director, Promoter
  • Mr. Knuettel, Chief Financial Officer
  • Mr. Clem, Chief Commercial Officer
  • Gerald Commissiong, Chief Business Officer
  • Paul Romness, Executive Officer
  • Jutta Wanner, Executive Officer
  • Robert Petit, Executive Officer

Verified email and direct lines for Os Therapies’s decision-makers are on Fundz. See plans

Os Therapies in the news

Companies similar to Os Therapies

About Os Therapies: questions and answers

What does Os Therapies do?

OS Therapies is a clinical stage research company focusing on therapeutic treatments for Osteosarcoma, Breast Cancer and other solid tumors with two platform technologies: OST-HER2 to prevent metastasis and OST-tADC to debulk solid tumors.

Where is Os Therapies headquartered?

Os Therapies is headquartered in Cambridge, Maryland, United States.

How many employees does Os Therapies have?

Os Therapies has about 5 employees.

Has Os Therapies raised funding?

Yes. Fundz has recorded 5 funding events for Os Therapies. The most recent, $5.0M, was in Aug 2026.

What is the latest news on Os Therapies?

On Oct 01, 2026, OS Therapies Appoints Mr. Clem as Chief Commercial Officer and Mr. Knuettel as Chief Financial Officer

Is Os Therapies a public company?

Yes. Os Therapies is publicly traded under the ticker OSTX.

Source: Fundz records from SEC filings, press releases and company announcements. How Fundz measures data accuracy

Fundz watches Os Therapies across 18 signal types, from funding and M&A to exec moves and hiring.

145 of these a day, filtered to the companies you pick, with the decision-maker attached.

5 screens from a live account. No signup.